A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors (Q41699326)
Jump to navigation
Jump to search
scientific article published on 10 December 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors |
scientific article published on 10 December 2014 |
Statements
1 reference
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors (English)
1 reference
1 reference
Filip Janku
1 reference
Zev A Wainberg
1 reference
Luis Paz-Ares
1 reference
Johan Vansteenkiste
1 reference
Eric Van Cutsem
1 reference
José Pérez-García
1 reference
Anastasios Stathis
1 reference
Carolyn D Britten
1 reference
Ngocdiep Le
1 reference
Kirsten Carter
1 reference
David Demanse
1 reference
Denes Csonka
1 reference
Malte Peters
1 reference
Angela Zubel
1 reference
Heidi Nauwelaerts
1 reference
Cristiana Sessa
1 reference
10 December 2014
1 reference
1 reference
Identifiers
1 reference